On Thursday, Shares of Synta Pharmaceuticals Corp. (NASDAQ:SNTA), surged 4.48% to $3.03.
Synta Pharmaceuticals, declared that poster presentations related to studies with ganetespib, a novel, potent small molecule inhibitor of heat shock protein 90 (Hsp90) in Phase 3 development, and STA-12-8666, the company’s leading candidate from its proprietary Hsp90 inhibitor Drug Conjugate (HDC) Program, will be presented at the 2015 Annual Meeting of the American Association of Cancer Research (AACR) in Philadelphia, Pennsylvania.
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients.
Shares of Gogo Inc. (NASDAQ:GOGO), gained 4.48% to $22.03, during the last trading session on Thursday, hitting its highest level.
Gogo, declared that it will release the results for its first quarter ended March 31, 2015 before the market open on May 7th, 2015. The company will host its quarterly earnings conference call the same day at 8:30 a.m. (ET).
The conference call will be held on May 7th, 2015 at 8:30 a.m. (ET). A live web cast of the conference call, in addition to a replay, will be accessible online on the Investor Relations section of the company’s website at http://ir.gogoair.com.
Gogo Inc., through its auxiliaries, provides aero communications services to the commercial and business aviation markets in the United States and internationally. The company operates three segments: Commercial Aviation North America, Commercial Aviation Rest of World, and Business Aviation.
At the end of Thursday’s trade, Shares of Castlight Health, Inc. (NYSE:CSLT), gained 4.38% to $7.87.
Castlight Health, declared that it has planned a conference call to review its first quarter 2015 results (ended March 31, 2015) for Wednesday, May 6, 2015 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).
Castlight Health, Inc. provides cloud-based software in the United States. Its software enables enterprises to understand and manage health care spending. It offers Enterprise Healthcare Cloud that transforms external and internal complex data into transparent and useful information.
Finally, BioLineRx, Ltd. (NASDAQ:BLRX), ended its Thursday’s trading session with 4.23% gain, and closed at $2.22.
On March 25, BioLineRx, declared successful top-line results from the Phase 1 safety and efficacy study of its lead clinical candidate, BL-8040, as a novel approach for mobilization and collection of bone-marrow stem cells from the peripheral blood circulation. All safety and efficacy endpoints were met, showing that treatment with BL-8040 as a single agent was safe and well tolerated at all doses and resulted in efficient stem cell mobilization and collection in all study participants. Importantly, the results support BL-8040 as one-day, single-dose collection regimen, which is a noteworthy improvement upon the current standard of care.
Robust stem cell mobilization was evident in all treated participants, across the different doses tested, supporting a novel approach to stem cell collection. After a single administration, BL-8040 enabled collection of a yield of stem cells that exceeds the number required to support a transplant in all treated participants, following only one collection procedure. The Company intends to present the full set of study results at the European Hematology Association (EHA) Conference taking place in Vienna in June 2015.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
